SUMOylation inhibition enhances dexamethasone sensitivity in multiple myeloma.

Li DuWei LiuGrace Aldana-MasangkayAlex PozhitkovFlavia PichiorriYuan ChenSteven T Rosen

Published in: Journal of experimental & clinical cancer research : CR (2022)

Our study proves SUMOylation plays a crucial role in Dex resistance in MM and SUMOylation inhibition appears to be an attractive strategy to advance to the clinic for MM patients.

Keyphrases

end stage renal disease
multiple myeloma
ejection fraction
newly diagnosed
primary care
low dose
prognostic factors
peritoneal dialysis
high dose